Literature DB >> 12183536

Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme.

Barbara A Fernie-King1, David J Seilly, Alexandra Davies, Peter J Lachmann.   

Abstract

Streptococcal inhibitor of complement (SIC) is a 31-kDa extracellular protein of a few, very virulent, strains of Streptococcus pyogenes (particularly M1 strains). It is secreted in large quantities (about 5 mg/liter) and inhibits complement lysis by blocking the membrane insertion site on C5b67. We describe investigations into the interaction of SIC with three further major components of the innate immune system found in airway surface liquid, namely, secretory leukocyte proteinase inhibitor (SLPI), lysozyme, and lactoferrin. Enzyme-linked immunosorbent assays showed that SIC binds to SLPI and to both human and hen egg lysozyme (HEL) but not to lactoferrin. Studies using (125)I-labeled proteins showed that SIC binds approximately two molecules of SLPI and four molecules of lysozyme. SLPI binding shows little temperature dependence and a small positive enthalpy, suggesting that the binding is largely hydrophobic. By contrast, lysozyme binding shows strong temperature dependence and a substantial negative enthalpy, suggesting that the binding is largely ionic. Lysozyme is precipitated from solution by SIC. Further studies examined the ability of SIC to block the biological activities of SLPI and lysozyme. An M1 strain of group A streptococci was killed by SLPI, and the antibacterial activity of this protein was inhibited by SIC. SIC did not inhibit the antiproteinase activity of SLPI, implying that there is specific inhibition of the antibacterial domain. The antibacterial and enzymatic activities of lysozyme were also inhibited by SIC. SIC is the first biological inhibitor of the antibacterial action of SLPI to be described and may prove to be an important tool for investigating this activity in vivo. Inhibition of the antibacterial actions of SLPI and lysozyme would be advantageous to S. pyogenes in establishing colonization on mucosal surfaces, and we propose that this is the principal function of SIC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183536      PMCID: PMC128256          DOI: 10.1128/IAI.70.9.4908-4916.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

Review 1.  Antimicrobial peptides and proteins in the innate defense of the airway surface.

Authors:  S M Travis; P K Singh; M J Welsh
Journal:  Curr Opin Immunol       Date:  2001-02       Impact factor: 7.486

2.  SELECTION OF GROUP A STREPTOCOCCI RICH IN M-PROTEIN FROM POPULATIONS POOR IN M-PROTEIN.

Authors:  C G BECKER
Journal:  Am J Pathol       Date:  1964-01       Impact factor: 4.307

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes.

Authors:  O Wiedow; J Harder; J Bartels; V Streit; E Christophers
Journal:  Biochem Biophys Res Commun       Date:  1998-07-30       Impact factor: 3.575

5.  Synergistic and additive killing by antimicrobial factors found in human airway surface liquid.

Authors:  P K Singh; B F Tack; P B McCray; M J Welsh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-11       Impact factor: 5.464

Review 6.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

7.  Innate antimicrobial activity of nasal secretions.

Authors:  A M Cole; P Dewan; T Ganz
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics.

Authors:  N P Hoe; P Kordari; R Cole; M Liu; T Palzkill; W Huang; D McLellan; G J Adams; M Hu; J Vuopio-Varkila; T R Cate; M E Pichichero; K M Edwards; J Eskola; D E Low; J M Musser
Journal:  J Infect Dis       Date:  2000-10-03       Impact factor: 5.226

9.  Identification of a novel secretory leukocyte protease inhibitor-binding protein involved in membrane phospholipid movement.

Authors:  C C Tseng; C P Tseng
Journal:  FEBS Lett       Date:  2000-06-23       Impact factor: 4.124

10.  Distribution of streptococcal inhibitor of complement variants in pharyngitis and invasive isolates in an epidemic of serotype M1 group A Streptococcus infection.

Authors:  N P Hoe; J Vuopio-Varkila; M Vaara; D Grigsby; D De Lorenzo; Y X Fu; S J Dou; X Pan; K Nakashima; J M Musser
Journal:  J Infect Dis       Date:  2001-01-17       Impact factor: 5.226

View more
  32 in total

Review 1.  Subversion of the innate immune response by micro-organisms.

Authors:  B Fernie-King; D J Seilly; A Davies; P J Lachmann
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

2.  Genomic location and variation of the gene for CRS, a complement binding protein in the M57 strains of Streptococcus pyogenes.

Authors:  Michael Binks; David McMillan; Kadaba S Sriprakash
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

3.  DRS is far less divergent than streptococcal inhibitor of complement of group A streptococcus.

Authors:  Vivek Sagar; Rajesh Kumar; Nirmal K Ganguly; Thangam Menon; Anuradha Chakraborti
Journal:  J Bacteriol       Date:  2007-01-19       Impact factor: 3.490

4.  Structural evidence for lack of inhibition of fish goose-type lysozymes by a bacterial inhibitor of lysozyme.

Authors:  Peter Kyomuhendo; Inge W Nilsen; Bjørn Olav Brandsdal; Arne O Smalås
Journal:  J Mol Model       Date:  2008-05-20       Impact factor: 1.810

Review 5.  Current insights in invasive group A streptococcal infections in pediatrics.

Authors:  Anne Filleron; Eric Jeziorski; Anne-Laure Michon; Michel Rodière; Hélène Marchandin
Journal:  Eur J Pediatr       Date:  2012-02-25       Impact factor: 3.183

6.  Sequence diversity of sicG among group C and G Streptococcus dysgalactiae subspecies equisimilis isolates associated with human infections in western Norway.

Authors:  O Oppegaard; H Mylvaganam; S Skrede; N Langeland; B R Kittang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-10       Impact factor: 3.267

7.  Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva.

Authors:  Samuel A Shelburne; Chanel Granville; Maria Tokuyama; Izabela Sitkiewicz; Payal Patel; James M Musser
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection.

Authors:  Tomas Fiedler; Catur Riani; Dirk Koczan; Kerstin Standar; Bernd Kreikemeyer; Andreas Podbielski
Journal:  Appl Environ Microbiol       Date:  2012-12-14       Impact factor: 4.792

10.  The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins.

Authors:  Barbara A Fernie-King; David J Seilly; Peter J Lachmann
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.